Breathe Well Live Well
|
AstraZeneca Symbicort shows similar safety profile as Budesonide for asthma
Pharmaceutical Business Review AstraZeneca has published a new study that demonstrates that Symbicort Inhalation Aerosol 320/9 µg twice daily has a safety profile similar to Budesonide pressurized metered-dose inhaler (pMDI) 320 µg twice daily for asthma. SYMBICORT® (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows … |
View full post on asthma – Google News
|
Budesonide Ups Expression of GILZ and FKBP51 in Asthma
Doctors Lounge Treatment with inhaled budesonide increases the expression of GILZ and FKBP51 in patients with atopic asthma, according to a study published online Aug. 9 in the British Journal of Pharmacology. FRIDAY, Aug. 19 (HealthDay News) — Treatment with … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: RNS60; Drug: Normal saline (Placebo); Drug: Budesonide (Pulmicort Respules)
Sponsor: Revalesio Corporation
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days